169 related articles for article (PubMed ID: 28125730)
1. The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis.
Frouws MA; Reimers MS; Swets M; Bastiaannet E; Prinse B; van Eijk R; Lemmens VE; van Herk-Sukel MP; van Wezel T; Kuppen PJ; Morreau H; van de Velde CJ; Liefers GJ
PLoS One; 2017; 12(1):e0170775. PubMed ID: 28125730
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
4. Statin Use After Diagnosis of Colon Cancer and Patient Survival.
Voorneveld PW; Reimers MS; Bastiaannet E; Jacobs RJ; van Eijk R; Zanders MMJ; Herings RMC; van Herk-Sukel MPP; Kodach LL; van Wezel T; Kuppen PJK; Morreau H; van de Velde CJH; Hardwick JCH; Liefers GJ
Gastroenterology; 2017 Aug; 153(2):470-479.e4. PubMed ID: 28512021
[TBL] [Abstract][Full Text] [Related]
5. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.
Popovici V; Budinska E; Tejpar S; Weinrich S; Estrella H; Hodgson G; Van Cutsem E; Xie T; Bosman FT; Roth AD; Delorenzi M
J Clin Oncol; 2012 Apr; 30(12):1288-95. PubMed ID: 22393095
[TBL] [Abstract][Full Text] [Related]
6. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
7. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.
Yoon HH; Shi Q; Alberts SR; Goldberg RM; Thibodeau SN; Sargent DJ; Sinicrope FA;
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26160882
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
[TBL] [Abstract][Full Text] [Related]
9. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.
Fariña-Sarasqueta A; van Lijnschoten G; Moerland E; Creemers GJ; Lemmens VEPP; Rutten HJT; van den Brule AJC
Ann Oncol; 2010 Dec; 21(12):2396-2402. PubMed ID: 20501503
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
[TBL] [Abstract][Full Text] [Related]
11. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
12. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.
Nitsche U; Rosenberg R; Balmert A; Schuster T; Slotta-Huspenina J; Herrmann P; Bader FG; Friess H; Schlag PM; Stein U; Janssen KP
Ann Surg; 2012 Nov; 256(5):763-71; discussion 771. PubMed ID: 23095620
[TBL] [Abstract][Full Text] [Related]
13. In vitro prediction of the efficacy of molecularly targeted cancer therapy by Raman spectral imaging.
Yosef HK; Mavarani L; Maghnouj A; Hahn S; El-Mashtoly SF; Gerwert K
Anal Bioanal Chem; 2015 Nov; 407(27):8321-31. PubMed ID: 26168967
[TBL] [Abstract][Full Text] [Related]
14. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
15. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
Gao J; Sun ZW; Li YY; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
[TBL] [Abstract][Full Text] [Related]
16. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.
Reimers MS; Bastiaannet E; Langley RE; van Eijk R; van Vlierberghe RL; Lemmens VE; van Herk-Sukel MP; van Wezel T; Fodde R; Kuppen PJ; Morreau H; van de Velde CJ; Liefers GJ
JAMA Intern Med; 2014 May; 174(5):732-9. PubMed ID: 24687028
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
18. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
19. Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients.
Revuelta I; Moya-Rull D; García-Herrera A; Rovira J; Ayala de la Peña F; Misiego A; Guzmán F; Oppenheimer F; Albanell J; Campistol JM
Transplantation; 2012 Mar; 93(5):509-17. PubMed ID: 22245873
[TBL] [Abstract][Full Text] [Related]
20. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
